Status:
UNKNOWN
Proactive Cardiovascular Prevention Strategy in Subjects With High Genetic Risk
Lead Sponsor:
Alar Irs
Collaborating Sponsors:
North Estonia Regional Hospital
Tartu University Hospital
Conditions:
Cardiovascular Diseases
Primary Prevention
Eligibility:
All Genders
30-70 years
Phase:
NA
Brief Summary
A polygenic risk score (PRS) will be developed and implemented into the primary care digital work-flow. 1000 study subjects with no known cardiovascular disease, diabetes or statin treatment and with...
Detailed Description
A polygenic risk score (PRS) will be developed and implemented into the primary care digital work-flow. 1000 study subjects with no known cardiovascular disease, diabetes or statin treatment and with...
Eligibility Criteria
Inclusion
- Male 30-65 years or female 40-70 years
- No history of ischemic heart disease, stroke, TIA or PAD in electronic health record
- No cholesterol lowering treatment
- No history of diabetes
- High PRS of CVD
- No physical or mental conditions precluding informed consent or participation
Exclusion
- History of ischemic heart disease, stroke, transitory ischemic attack (TIA) or peripheral artery disease (PAD) in electronic health record
- Cholesterol lowering treatment
- History of diabetes
- No consent to participate
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04291157
Start Date
March 1 2019
End Date
December 31 2020
Last Update
March 2 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
North Estonia Medical Centre
Tallinn, Estonia, 13419
2
Tartu University Hospital
Tartu, Estonia, 50406